Codexis Inc. has acquired Julich Fine Chemicals GmbH (JFC), a supplier of specialty enzymes for organic synthesis and chiral building blocks. Financial terms are not being disclosed.
“The acquisition of JFC is part of our strategic expansion into international markets, in particular Europe,” says Alan Shaw, president and CEO of Codexis. “We believe it will accelerate adoption of Codexis’s biocatalytic approach to pharmaceutical process research and manufacturing, an area historically dominated by synthetic organic chemistry.”
Founded in 1999, JFC supplies products and services for the biocatalytic production of chiral pharmaceutical intermediates to the European market. Through its catalog, JFC offers a range of off-the-shelf specialty enzymes and chiral intermediates useful in pharmaceutical development. JFC will operate as an independent, wholly owned subsidiary of Codexis, providing an outlet for several of Codexis’s proprietary enzymes.
“Synergies between our companies can lead to accelerated revenue growth and greater market presence in Europe,” Mr. Shaw says. “Codexis will continue to leverage its MolecularBreeding technology platform, streamlining Phase I and Phase II drug development and creating valuable intellectual property for our pharmaceutical partners.”
Codexis expects the acquisition to make a positive cash contribution during the first full year of operation.
Thomas Daussmann, managing director of JFC, will join the Codexis leadership team. “Our companies bring complementary expertise and market knowledge to the complex manufacturing challenges facing today’s pharmaceutical companies,” he says. “We look forward to being part of Codexis as we address this rapidly growing worldwide market.”
Alan Shaw, president and CEO of Codexis.